Smart Investing

Be an active trader but let Tradey do the work for you

Stock Analysis

Continuous updates for attractiveness

Market Analysis

Reduce risk in risky markets

Profits

Improve your profits

Tradey is a smart investment bot that determines a trading strategy on its own based on historic and fresh data. By considering many parameters and suggesting trades based on that basis Tradey will try to maximize your investment return. We try to take our human and emotional trading on the sidelines and let the bot decide the right strategy based on algorithms to reach an optimal trading strategy.

Tradey has three key tasks: (1) to find the most interesting stocks in the stock universe to buy right now, (2) to continuously examine the expectation for alpha for the stocks and by that means decide when a stock can better be sold, (3) to examine the market as a whole to prevent trading for growth (not short) in bear markets (or recessions).

T10

STLD Steel Dynamics, Inc. 0.85
ADM Archer Daniels Midland Company 0.84
FBIZ First Business Financial Services, Inc. 0.82
MRK Merck & Company 0.81
CRAI CRA International, Inc. 0.81
HAL Halliburton Company 0.8
RS Reliance Steel & Aluminum Co. 0.8
BBSI Barrett Business Services, Inc. 0.8
DCP DCP Midstream LP 0.8
NRIM Northrim BanCorp Inc 0.8

The 10 stocks above are currently the most attractive ones according to Tradey.

Annualized outperformance (w/o costs): 37.06% (p.p., from 2020-06-01)

News

The US stock market closed mixed, Dow Jones did not rise in price
The US stock market closed mixed, Dow Jones did not rise in price

InstaForex At the close of the day on the New York Stock Exchange, the Dow Jones did not rise in price, the S&P 500 index fell 0.19%, the NASDAQ Composite index fell 0.51%. The leading performer among the components of the Dow Jones index today was 3M Company, which gained 1.77 points (1.42%) to close at 126.35. Merck & Company Inc rose 1.16 points or 1.06% to close at 110.09. Amgen Inc rose 0.87% or 2.47 points to close at 285.76. The biggest losers were Salesforce Inc, which shed 2.79 points or 2.09% to end the session at 130.48. Apple Inc. shares rose 1.97 points (1.38%) to close at 140.94, while Boeing Co was down 1.93 points (1.08%) to close at 176.50. . Leading gainers among the S&P 500 index components in today''s trading were State Street Corp, which rose 8.19% to hit 80.45, Campbell Soup Company, which gained 6.02% to close at 56.18, and also shares of Bank of New York Mellon, which rose 4.13% to close the session at 44.61. The biggest losers were M&T Bank Corp, which shed 7.72% to close at 147.97. more…

Do Multifactor Funds Deliver on Their Objective?
Do Multifactor Funds Deliver on Their Objective?

Morningstar Our latest paper tries to unlock the mysteries of multifactor funds. more…

GSK''s Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial
GSK''s Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial

Benzinga GSK plc (NYSE: GSK ) announced results from the PERLA phase 2 trial investigating Jemperli (dostarlimab) + chemotherapy versus Merck & Co Inc''s (NYSE: MRK ) Keytruda pembrolizumab + chemo as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). Dostarlimab plus chemotherapy achieved promising results for the primary endpoint of confirmed objective response rate … Full story available on Benzinga.com more…

Corrections and Clarifications
Corrections and Clarifications

Morningstar more…

10 Cheap Stocks With Safe Dividends
10 Cheap Stocks With Safe Dividends

Morningstar These stocks in the Morningstar Dividend Yield Focus Index look undervalued today. more…

A Year-End Bucket To-Do List
A Year-End Bucket To-Do List

Morningstar These seven steps tackle a lot of jobs: refilling cash, rebalancing, tax planning, and charitable giving. more…

Mirati stock dips amid trial data on adagrasib/Keytruda combo in lung cancer patients
Mirati stock dips amid trial data on adagrasib/Keytruda combo in lung cancer patients

Seeking Alpha Mirati Therapeutics (MRTX -0.1%) said its medicine adagrasib in combination with Merck''s (MRK) Keytruda (pembrolizumab) showed favorable tolerability and promising preliminary efficacy… more…

Meta May Be Fined, See Its Data Collection Policies Upended by European Regulators
Meta May Be Fined, See Its Data Collection Policies Upended by European Regulators

Morningstar Maintaining $260 fair value estimate, shares attractive. more…

Software Stocks Are Cheap, but Is It a Safe Time to Buy?
Software Stocks Are Cheap, but Is It a Safe Time to Buy?

Morningstar Stocks like MongoDB, Snowflake, and ServiceNow are at big discounts, but a murky revenue outlook clouds the picture. more…

The Best Funds for Rebalancing in 2023
The Best Funds for Rebalancing in 2023

Morningstar These top-rated ETFs and mutual funds can bring balance to portfolios with off-kilter asset allocations. more…

Train Your Brain to Handle Market Uncertainty
Train Your Brain to Handle Market Uncertainty

Morningstar Why emotional coping is an essential skill for long-term investors. more…

Top 10 Buys and Sells From Our Ultimate Stock-Pickers
Top 10 Buys and Sells From Our Ultimate Stock-Pickers

Morningstar Funds see value in a diverse range of sectors. more…

Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients

Financial Post Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co’s immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday. The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, […] more…

Jim Cramer’s Investing Club meeting Monday: Oil sale, Starbucks
Jim Cramer’s Investing Club meeting Monday: Oil sale, Starbucks

Bitcoin Ethereum News The post Jim Cramer’s Investing Club meeting Monday: Oil sale, Starbucks appeared on BitcoinEthereumNews.com . Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. Trimming HAL SBUX downgrade LLY… more…

Is the Market Still Undervalued After the Recent Rally?
Is the Market Still Undervalued After the Recent Rally?

Morningstar We expect more turbulence ahead. more…

Today’s Market: Bonds vs. Bond Funds
Today’s Market: Bonds vs. Bond Funds

Morningstar Has there been a meaningful difference? more…

15 Funds That Have Destroyed the Most Wealth Over the Past Decade
15 Funds That Have Destroyed the Most Wealth Over the Past Decade

Morningstar These funds managed to lose value for shareholders even during a generally bullish market. more…

Time To Take Profits On These Recent Breakout Stocks?
Time To Take Profits On These Recent Breakout Stocks?

Bitcoin Ethereum News The post Time To Take Profits On These Recent Breakout Stocks? appeared on BitcoinEthereumNews.com . Breakout stocks Steel Dynamics (STLD) and Pinduoduo (PDD) are hitting new highs and stand among the few recent market winners. X Investors may be wondering if now is a good… more…

Injectable Pain Medication Market to Witness Huge Growth by Key Players: Merck, Pfizer, Novartis, Sanofi, Bayer, Boehringer Ingelheim
Injectable Pain Medication Market to Witness Huge Growth by Key Players: Merck, Pfizer, Novartis, Sanofi, Bayer, Boehringer Ingelheim

OpenPR The Injectable Pain Medication research report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive more…

McCormick, PulteGroup, and Merck Boost Dividends
McCormick, PulteGroup, and Merck Boost Dividends

Barron''s Seasonings maker McCormick, home builder PulteGroup, and drug giant Merck are among the large-cap firms that announced increased dividends in the past week. more…

Merck leans on new Keytruda formulation to avoid patent cliff
Merck leans on new Keytruda formulation to avoid patent cliff

Seeking Alpha Merck (MRK) is unlikely to allow competition to hurt prospects for its blockbuster cancer therapy Keytruda anytime soon, with a Reuters report on Friday indicating that the company… more…

TBOM

2022-12-08

0.513

S&P

2022-11-04

3763.50

T-bill 10y/3m

2022-02-18

1.92 / 0.35

BCIg

2022-11-17

9.35